What's in Padagis LLC's pipeline?

Padagis LLC has 20 drugs in our index: 3 marketed, 0 filed, 12 in Phase 3, 1 in Phase 2, 4 in Phase 1.

Which companies overlap with Padagis LLC's portfolio?

Top competitors by shared drug class: Actavis Inc., Galderma R&D, LEO Pharma, University Health Network, Toronto, GWT-TUD GmbH.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/padagis-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Padagis LLC — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Padagis LLC pipeline: 3 marketed, 0 filed, 12 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 12 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Adapalene and Benzoyl Peroxide Gel	Adapalene and Benzoyl Peroxide Gel	marketed	Retinoid [EPC]
Uceris	Uceris	marketed			Other
Zoryve	Zoryve	marketed			Other
Brinzolamide/brimonidine ophthalmic suspension	Brinzolamide/brimonidine ophthalmic suspension	phase 3	Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination	Carbonic anhydrase II; Alpha-2 adrenergic receptor	Ophthalmology
Acanya Gel	Acanya Gel	phase 3	Topical antibiotic combination	Cutibacterium acnes (bacterial protein synthesis inhibition); benzoyl peroxide acts as an oxidizing antimicrobial	Dermatology
Azelaic acid foam	Azelaic acid foam	phase 3	Topical antimicrobial and anti-inflammatory agent		Dermatology
Azopt 1% Ophthalmic Suspension	Azopt 1% Ophthalmic Suspension	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase II	Ophthalmology
Epiduo Topical Product	Epiduo Topical Product	phase 3	Retinoid + peroxide combination	Retinoic acid receptor (adapalene); bacterial cell membrane disruption (benzoyl peroxide)	Dermatology
Ingenol Mebutate (Reference)	Ingenol Mebutate (Reference)	phase 3	Protein kinase C (PKC) activator	Protein kinase C (PKC)	Dermatology
estrace cream (Reference)	estrace cream (Reference)	phase 3
estrace cream (Perrigo)	estrace cream (Perrigo)	phase 3
Acyclovir 5 percent (Perrigo)	Acyclovir 5 percent (Perrigo)	phase 3	Nucleoside analog antiviral	Viral DNA polymerase	Infectious Disease / Virology

Therapeutic area mix

Dermatology · 6
Ophthalmology · 2
Other · 2
Dermatology / Oncology · 1
Infectious Disease · 1
Infectious Disease / Virology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Actavis Inc. · 4 shared drug classes
Galderma R&D · 3 shared drug classes
LEO Pharma · 3 shared drug classes
University Health Network, Toronto · 3 shared drug classes
GWT-TUD GmbH · 2 shared drug classes
Beijing Tiantan Hospital · 2 shared drug classes
Bausch & Lomb Incorporated · 2 shared drug classes
· 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Padagis LLC:

Cite this brief

Drug Landscape (2026). Padagis LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/padagis-llc. Accessed 2026-06-10.